Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928522 | 0.96 | KDM4E (0.54) | KDM4EALDH1A1DRD4DRD2DRD3 | |
| SCHEMBL24573017 | 0.96 | KDM4E (0.54) | KDM4EALDH1A1DRD4DRD2DRD3 | |
| SCHEMBL9811777 | 0.96 | KDM4E (0.54) | KDM4EALDH1A1DRD4DRD2DRD3 | |
| SCHEMBL4598755 | 0.89 | DRD4 (0.53) | KDM4EALDH1A1DRD4DRD2DRD3 | |
| SCHEMBL4598588 | 0.89 | DRD4 (0.53) | KDM4EALDH1A1DRD4DRD2DRD3 | |
| SCHEMBL8339774 | 0.88 | MAPT (0.52) | KDM4ERECQLL3MBTL1MAPTLTA4H | |
| SCHEMBL6557649 | 0.88 | MAOB (0.57) | KDM4EALDH1A1DRD4DRD2DRD3 | |
| SCHEMBL6133006 | 0.87 | DRD4 (0.51) | KDM4EALDH1A1DRD4DRD2DRD3 | |
| SCHEMBL29749908 | 0.87 | KDM4E (0.49) | KDM4EALDH1A1DRD4DRD2DRD3 | |
| SCHEMBL6132842 | 0.87 | DRD4 (0.51) | KDM4EALDH1A1DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4532484-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| CN-119173509-A | ROCK inhibitors and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| US-6197770-B1 | ENZYME INHIBITORS; ANTIARTHRITIC AGENTS; BONE DISORDERS | THE PROCTER & GAMBLE CO. | 2001-03-06 | — | — | US | disclosed |
| WO-2000051975-A1 | ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000044739-A1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000037455-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-06-29 | — | — | WO | disclosed |
| EP-0944587-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-09-29 | — | — | EP | disclosed |
| US-5840974-A | Metalloproteinase inhibitors | BRITISCH BIOTECH PHARMACEUTICALS, LTD. (GB) | 1998-11-24 | — | — | US | disclosed |
| CN-1039331-C | Depsispeptide derivative, preparation and application of same | FUJISAMA PHARMACEUTICAL CO LTD (JP) | 1998-07-29 | — | — | CN | disclosed |
| WO-1998024759-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-06-11 | — | — | WO | disclosed |
| US-5514773-A | PARASITICIDES, ANTHELMINTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-07 | — | — | US | disclosed |
| EP-0634408-A1 | DEPSIPEPTIDE DERIVATIVE, PRODUCTION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346616-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, RHOA | KDM4E 2213/4885ALDH1A1 2229/4885DRD4 4653/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | KDM4E 4213/4885ALDH1A1 2066/4885DRD4 4873/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | KDM4E 4241/4885ALDH1A1 2144/4885DRD4 4878/4885 |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | KDM4E 1206/4885ALDH1A1 1591/4885DRD4 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.